Core Viewpoint - Calidi Biotherapeutics Inc. is hosting a webinar to discuss its innovative cell-based delivery platforms for cancer treatment, highlighting its lead programs targeting various types of tumors [1][2]. Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted antitumor virotherapies using proprietary technology to enhance the immune system's ability to fight cancer [4]. - The company utilizes allogeneic stem cells to deliver oncolytic viruses, aiming to improve efficacy and patient safety in treating high-grade gliomas and solid tumors [4]. Webinar Details - The webinar is scheduled for February 5, 2025, at 4:15 p.m. ET, featuring insights from CFO Andrew Jackson and CSO Antonio F. Santidrian [1][2]. - Attendees will receive an overview of Calidi's lead programs, including CLD-400 for metastatic cancers, CLD-201 for advanced solid tumors, and CLD-101 for high-grade glioma, followed by a live Q&A session [2]. Registration Information - Interested participants can register for the free webinar through a provided link and submit questions in advance [3].
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5